Ready-to-Use Norepinephrine IV Solution Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current norepinephrine IV solutions require dilution, introducing risks of microbial contamination and antioxidant-related health issues, and have limited storage stability at room temperature, necessitating the development of a ready-to-use, storage-stable solution without dextrose and antioxidants.
Innovation Solution
A ready-to-use norepinephrine IV solution in flexible plastic bags, formulated with a pharmaceutically acceptable salt, tonicity adjusting agents like sodium chloride, and an oxygen absorber, which maintains stability at room temperature for 12 to 24 months without the need for antioxidants or dextrose, ensuring isotonicity and pH control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If concentrated norepinephrine solutions are diluted in IV solution, then the norepinephrine concentration is adjusted to therapeutic range, but the risk of microbial contamination and dilution errors increases
Solution Approach 1:
The norepinephrine solution is prepared at the exact therapeutic concentration (0.016-0.064 mg/ml) during manufacturing, eliminating the need for dilution at the point of use. This preliminary preparation of the final concentration ensures both accuracy and sterility, as the solution is ready for immediate administration without additional handling steps that could introduce contamination or dosing errors.
2Stability of the object's composition
If antioxidants such as sodium metabisulfite are added to concentrated norepinephrine solutions, then storage stability is improved, but health risks are introduced
Solution Approach 1:
The antioxidant component (sodium metabisulfite) is completely removed from the formulation. Instead of relying on antioxidants to prevent degradation, the invention uses a different approach: preparing the norepinephrine at therapeutic concentration and formulating it with isotonic agents (0.9% sodium chloride or 5% dextrose) to maintain stability without harmful additives.
Solution Approach 2:
The solution concentration parameter is changed from concentrated (1 mg/ml) to therapeutic range (0.016-0.064 mg/ml), which fundamentally alters the stability requirements and eliminates the need for antioxidants. The lower concentration reduces oxidation risk while maintaining therapeutic efficacy.
3Stability of the object's composition
If dextrose solution is used for dilution, then pH control is improved, but the risk ofhyperglycemia increases
Solution Approach 1:
The invention changes the formulation approach by preparing norepinephrine directly at therapeutic concentration with isotonic agents, eliminating the need for dilution with dextrose. This avoids the hyperglycemia risk while maintaining pH control through proper formulation during manufacturing.
Solution Approach 2:
Dextrose is removed from the formulation options. Instead of using dextrose-based dilution solutions, the invention uses 0.9% sodium chloride as the vehicle, which provides isotonicity without contributing to blood glucose levels, thereby eliminating thehyperglycemia risk.
4Volume of stationary object
If concentrated norepinephrine solutions are stored, then storage space efficiency is improved, but the need for dilution and handling increases complexity
Solution Approach 1:
The solution is prepared in advance at the exact therapeutic concentration needed for administration. This preliminary preparation eliminates all subsequent dilution steps, reducing preparation complexity while maintaining storage efficiency. The ready-to-use formulation requires only simple connection to the infusion pump.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable, ready-to-use norepinephrine IV formulation that is free from dilution errors and antioxidant risks, with extended storage life at room temperature, maintaining norepinephrine concentration and pH stability, thus enhancing safety and usability in medical settings.
Implementation Method 1
an oxygen absorber, which maintains stability at room temperature for 12 to 24 months
Data Source
AI summary
A sterile, sulfite-free aqueous norepinephrine solution comprising up to about 0.2 mg/ml of norepinephrine concentration (as free base), a tonicity adjusting agent, at a pH where the norepinephrine is soluble which is packaged in a flexible plastic container, characterized by being storage stable for from about 12 months to about 24 months at room temperature of about 25° C.